3
Participants
Start Date
November 30, 1998
Primary Completion Date
May 31, 2000
Study Completion Date
May 31, 2000
irofulven
Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
San Antonio Cancer Institute, San Antonio
Brooke Army Medical Center, Fort Sam Houston
University of Nebraska Medical Center, Omaha
National Cancer Institute (NCI)
NIH
University of Texas
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
The University of Texas Health Science Center at San Antonio
OTHER